AI Article Synopsis
- The study assessed the real-life effectiveness and safety of erenumab in treating migraine in 33 patients, primarily females with an average age of 39.2 years.
- During the treatment, a significant 50% reduction in headache days was reported by nearly half of the patients across the first three months, along with improvements in pain intensity and the impact on daily activities as measured by HIT-6 scores.
- Side effects were minimal, with only one instance of transient constipation, suggesting that erenumab is both effective and safe for outpatient use in managing migraines.
Article Abstract
Objective: To assess the effectiveness and safety of erenumab in real-life study.
Material And Methods: 33 patients with episodic and chronic migraine (30 females, mean age 39.2±9.2, 3 males, mean age - 49.3±7.6) received erenumab 70 mg for each 3 months. Patients achieved a 50% reduction in the number of days with headache, pain intensity, duration, the number of days of acute medication use, effect on daily activity (HIT-6), side effects, neuropsychological testing (Beck Depression scale, Spielberger-Khanin questionnaire, Hospital Depression and Anxiety Scale) were assessed.
Results: During the first month of therapy, a 50% decrease in headache days was observed in 48% of patients, during the second - in 53% of patients, during the third - in 51.5% of patients (<0.001), a reduce in pain intensity, HIT-6 score, duration of migraine attack was observed (<0.005). A decrease in situational anxiety was revealed (Spielberger-Khanin questionnaire, =0.02), but not depression. There was a decrease in the consumption of triptans (<0.0005) and other analgesics (=0.0018). 1 patient noted transient constipation.
Conclusion: The effectiveness and safety of erenumab in the outpatient practice is shown.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.17116/jnevro202212207174 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!